Literature DB >> 620910

Bioavailability of cimetidine in man.

S S Walkenstein, J W Dubb, W C Randolph, W J Westlake, R M Stote, A P Intoccia.   

Abstract

The bioavailability of parenteral cimetidine was tested in 12 volunteers in a balanced three-way crossover study. Blood levels and urinary excretion were compared after intramuscular and intravenous injection and oral administration of 300 mg of cinetidine. The results indicated that the intramuscular and intravenous routes are virtually interchangeable for parenteral cimetidine, and that the oral liquid, although exhibiting a reduced area under the blood level curve as compared with the parenteral doses, nevertheless demonstrated equivalence with respect to the time the blood level remained above 0.5 microgram per ml. The 300-mg cimetidine tablet formulation was found in another group of 12 volunteers to be bioequivalent to a 300-mg dose of oral liquid.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 620910

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  63 in total

1.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Comments on two recent deconvolution methods.

Authors:  D Verotta
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

Review 3.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

4.  Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.

Authors:  A B Suttle; G M Pollack; K L Brouwer
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

Review 5.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

6.  Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.

Authors:  T Takabatake; H Ohta; M Maekawa; Y Yamamoto; Y Ishida; H Hara; S Nakamura; Y Ushiogi; M Kawabata; N Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

8.  Cimetidine-a clinical and pharmacokinetic study.

Authors:  J Webster; H E Barber; G M Hawksworth; T A Jeffers; J Petersen; J C Petrie; P W Brunt; N A Mowat; R Griffiths
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

9.  Pharmacokinetics of the H2- receptor antagonist ranitidine in man.

Authors:  J J McNeil; G W Mihaly; A Anderson; A W Marshall; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

10.  Effect of pancreatico-biliary secretions and GI transit time on the absorption and pharmacokinetic profile of ranitidine in humans.

Authors:  K S Reynolds; M H Song; W D Heizer; C B Burns; D A Sica; K L Brouwer
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.